Editas Medicine Inc (NASDAQ: EDIT) started the day on Thursday, with a price decrease of -5.11% at $1.30, before settling in for the price of $1.37 at the close. Taking a more long-term approach, EDIT posted a 52-week range of $1.12-$11.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 135.89%. Meanwhile, its Annual Earning per share during the time was 2.88%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -33.69%. This publicly-traded company’s shares outstanding now amounts to $82.54 million, simultaneously with a float of $81.78 million. The organization now has a market capitalization sitting at $107.31 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5446, while the 200-day Moving Average is $3.6616.
Editas Medicine Inc (EDIT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Editas Medicine Inc’s current insider ownership accounts for 0.93%, in contrast to 67.58% institutional ownership. According to the most recent insider trade that took place on Dec 03 ’24, this organization’s CEO sold 1,618 shares at the rate of 2.08, making the entire transaction reach 3,361 in total value, affecting insider ownership by 312,106. Preceding that transaction, on Dec 03 ’24, Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for 2.08, making the whole transaction’s value amount to 1,124. This particular insider is now the holder of 133,354 in total.
Editas Medicine Inc (EDIT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
Editas Medicine Inc’s EPS decrease for this current 12-month fiscal period is -33.69% and is forecasted to reach -1.39 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 15.23% through the next 5 years, which can be compared against the 2.88% growth it accomplished over the previous five years trading on the market.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Let’s observe the current performance indicators for Editas Medicine Inc (EDIT). It’s Quick Ratio in the last reported quarter now stands at 3.75. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.74.
In the same vein, EDIT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.56, a figure that is expected to reach -0.38 in the next quarter, and analysts are predicting that it will be -1.39 at the market close of one year from today.
Technical Analysis of Editas Medicine Inc (EDIT)
If we take a close look at the recent performances of Editas Medicine Inc (NASDAQ: EDIT), its last 5-days Average volume was 1.3 million that shows plunge from its year to date volume of 2.27 million. During the previous 9 days, stock’s Stochastic %D was recorded 39.80% While, its Average True Range was 0.1116.
Raw Stochastic average of Editas Medicine Inc (EDIT) in the period of the previous 100 days is set at 6.00%, which indicates a major fall in contrast to 45.45% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 70.44% that was lower than 84.40% volatility it exhibited in the past 100-days period.
